Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada
TI rates for mCSPC are suboptimal in Canada especially for older patients and those with recurrent mCSPC. TI prioritization in such groups may improve patient outcomes.
Authors
- Steven Yip (ORCID: https://orcid.org/0000-0003-2802-6651)
- Andrew Chilelli (ORCID: https://orcid.org/0009-0006-7086-4703)
- Winson Y. Cheung (ORCID: https://orcid.org/0000-0002-3679-4290)
- Kelvin Wong (ORCID: https://orcid.org/0000-0002-9871-1665)
- Dylan Edmund O'Sullivan (ORCID: https://orcid.org/0000-0002-2562-0017)
- A. Pranzo
- Matthias Stoelzel (ORCID: https://orcid.org/0000-0002-2058-7385)
- Thomas W. McLean (ORCID: https://orcid.org/0000-0001-6535-9450)
- Armen Garo Aprikian
Institutions
- Alberta Health Services (CA)
- University of Calgary (CA)
- Astellas Pharma (China) (CN)
- Astellas Pharma (United Kingdom) (GB)
- Astellas Pharma (Germany) (DE)
- Astellas Pharma (Netherlands) (NL)
- McGill University (CA)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-03-24
- DOI
- https://doi.org/10.1080/14796694.2025.2479374
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Pfizer